drugset / Trial / NCT03433248
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The current study aims to explore the clinical effects and mechanistics of mono- and combination therapy with SGLT-2 inhibitor empagliflozin and DPP-4 inhibitor linagliptin on renal physiology and biomarkers in metformin-treated T2DM patients.
Timeline
- Start
- 2017-11-09
- Primary completion
- 2021-06-01
- Completion
- 2022-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Gliclazide | Small molecule | 30 mg | Oral |
| Subject | Linagliptin | Small molecule | 5 mg | Oral |